🔎 Trials Near Me

መነሻ › Multiple Myeloma › Virginia

በVirginia ለMultiple Myeloma የሚደረጉ ክሊኒካዊ ጥናቶች

ለMultiple Myeloma የሚደረጉ 20 ጥናቶች በVirginia ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በVirginia ውስጥ ያሉ ከተሞች

Official study text (English)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Gainesville
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT07391657

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  • Virginia Commonwealth University - Massey Cancer Center, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06500884

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

  • Research Site, Charlottesville
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07073547

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • Alexander T. Augusta Military Medical Center, Fort Belvoir
  • Virginia Oncology Associates Brock Cancer Center, Norfolk
  • Richmond VA Medical Center, Richmond
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05552222

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  • Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
  • Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Inova Schar Cancer Institute, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT02693535

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

  • VCU Massey Comprehensive Cancer Center, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06465316

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Virginia Oncology Associates, Norfolk
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06297226

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  • Research Site, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ኦገስ 2026 · NCT06106945

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Charlottesville
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኦገስ 2026 · NCT07764978

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT05650632

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Sovah Health Martinsville, Martinsville
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ10 ጁን 2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • Virginia Oncology Associates, Norfolk
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ጁን 2026 · NCT05243797

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

  • Virginia Oncology Associates, Norfolk
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 19 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ጁን 2026 · NCT06974786

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  • GSK Investigational Site, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ኤፕሪ 2026 · NCT06679101

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  • Virginia Cancer Specialists, Fairfax
  • Blue Ridge Cancer Center, Roanoke
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ኤፕሪ 2026 · NCT05972135

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • University of Virginia, Charlottesville
  • Virginia Cancer Specialists, Fairfax
  • Virginia Oncology Associates, Norfolk
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • Virginia Commonwealth University, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2025 · NCT05722418

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  • NEXT Oncology Virginia, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ጁን 2025 · NCT06119685

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።